Cereno Scientific – executive interview

Cereno Scientific (OMX: CRNO-B) is a clinical-stage biotech focused on developing innovative, effective and safe treatments for cardiovascular diseases (CVD) and pulmonary diseases. The company has an exciting pipeline targeting unmet needs in CVD, with two clinical programmes and one preclinical programme. Lead candidate CS1 is a histone deacetylase inhibitor (HDACi) with epigenetic modulation properties, showing promise as a potentially disease-modifying treatment for pulmonary arterial hypertension (PAH), a rare, debilitating and progressive condition with no curative therapies. The Phase IIa data for CS1 in PAH were positive, and management is gearing up for discussions with regulators on a potential Phase IIb or pivotal Phase IIb/III study. The potential of Cereno’s HDACi programme to reverse disease progression in PAH was also highlighted in preclinical data reported for CS014, the company’s other HDACi programme. Second asset CS014 is currently in Phase I and Cereno recently announced that idiopathic pulmonary fibrosis will be the target indication for the candidate as part of a strategic pivot to strengthen the company’s focus on rare diseases. The third, preclinical, asset CS585 is a novel prostacyclin receptor agonist and is currently under evaluation for CVD, backed by encouraging preclinical data. Management hopes to start Phase I studies for CS585 in 2026, likely targeting a rare disease.

In this video, we talk to Sten Sörensen, CEO of Cereno Scientific, about the company’s strategic pivot to focus on rare diseases, how the recent SEK250m fundraise will be used to advance Cereno’s pipeline activities, as well as key milestones and catalysts that investors should watch out for as we move into 2025.